ObsEva SA announced the appointment of Fabien de Ladonchamps as chief executive officer of the company, effective on or about May 1, 2023. Mr. de Ladonchamps is a biotech executive with 25 years of experience in finance and administrative roles, primarily with Swiss biotech companies. He was a member of ObsEva's Executive Committee from October 2013 to July 2022, during which he had held the roles of Chief Administrative Officer and Interim Chief Financial Officer.

He also served as the sole finance and accounting officer for the company for a total of four years during which over $110 Million in equity proceeds were raised through private and public financings. Mr. de Ladonchamps was instrumental in the company's listings on both Nasdaq in 2017 and the Swiss Exchange in 2018. Prior to joining ObsEva, Mr. de Ladonchamps held a variety of management roles at Addex Therapeutics, from 2008 to 2013.

Mr. de Ladonchamps holds a degree in Finance and Accounting from the Lyon III University in Lyon, France. The company's Interim Chief Executive Officer, Will Brown, will serve in that position until Mr. Ladonchamps' effective date of service on May 1, 2023.